Aurora Cannabis' (ACB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Aurora Cannabis' stock is currently rated as a "Sell (D-)" by Weiss Ratings, with other analysts also expressing bearish sentiments on the stock.
• The company recently reported a net loss per share of ($0.19), significantly missing analysts' estimates of $0.18, and revenue of $71.98 million, below expectations.
• Aurora Cannabis' market capitalization stands at $342.94 million, with hedge funds collectively owning 47.63% of the stock.

Aurora Cannabis (NASDAQ:ACB - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently issued reports on ACB. Wall Street Zen downgraded Aurora Cannabis from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Zacks Research raised Aurora Cannabis from a "strong sell" rating to a "hold" rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy".

Aurora Cannabis Price Performance

NASDAQ:ACB traded down $0.07 during trading hours on Wednesday, reaching $6.10. The company had a trading volume of 2,056,138 shares, compared to its average volume of 1,867,908. The stock has a 50-day moving average of $5.09 and a two-hundred day moving average of $4.87. Aurora Cannabis has a one year low of $3.42 and a one year high of $6.91. The firm has a market capitalization of $342.94 million, a PE ratio of -32.11 and a beta of 1.75. The company has a quick ratio of 1.51, a current ratio of 2.97 and a debt-to-equity ratio of 0.06.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.37). Aurora Cannabis had a negative return on equity of 1.49% and a negative net margin of 5.66%.The business had revenue of $71.98 million during the quarter, compared to analyst estimates of $96.83 million. Analysts forecast that Aurora Cannabis will post 0.46 earnings per share for the current year.

Hedge Funds Weigh In On Aurora Cannabis

A number of hedge funds have recently added to or reduced their stakes in ACB. DKM Wealth Management Inc. purchased a new stake in shares of Aurora Cannabis during the 2nd quarter valued at about $42,000. JW Asset Management LLC purchased a new stake in shares of Aurora Cannabis during the 1st quarter valued at about $58,000. Cobblestone Asset Management LLC purchased a new stake in shares of Aurora Cannabis during the 1st quarter valued at about $67,000. Headlands Technologies LLC purchased a new stake in shares of Aurora Cannabis during the 2nd quarter valued at about $66,000. Finally, Millennium Management LLC purchased a new stake in shares of Aurora Cannabis during the 4th quarter valued at about $67,000. 47.63% of the stock is currently owned by hedge funds and other institutional investors.

Aurora Cannabis Company Profile

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.